Fangsheng Pharmaceutical (603998.SH): National Health Insurance Catalogue for Company Product Renewals (2026)

Zhitongcaijing · 2d ago

Zhitong Finance App News, Fangsheng Pharmaceutical (603998.SH) issued an announcement. On November 14, 2026, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Notice Concerning Issuance and (2026)” [Medical Insurance<国家基本医疗保险、生育保险和工伤保险药品目录> (2026) No. 29]. According to the notice, the company's children's Jingxing cough tablets and Xuanqijian bone tablets will now continue to be included in the “<商业健康保险创新药品目录> 2026 Medical Insurance Catalogue” in accordance with simple renewal rules. The company, wholly-owned, Other major products of the holding subsidiary have not been withdrawn or added to the “2026 Medical Insurance Catalogue”.

Children's Jingxing cough tablets and Xuanqijian bone tablets are all innovative traditional Chinese medicine drugs independently developed by the company. After continuing to be included in the “2026 Medical Insurance Catalogue”, they will facilitate the market promotion of these products, hospital entry and sales scale increase, and are expected to have a positive impact on the company's operating performance and market share.